Nanovibronix宣布，其全资子公司Envue Medical Holdings已获得该公司将电磁导航数据叠加到实时医学成像的专有方法的美国专利

Patent strengthens company's leadership in feeding tube placement and opens path to broader vascular navigation market

NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,402,953 B2, titled "Insertion Device Positioning Guidance System and Method" on September 2, 2025 to ENvue Medical Holdings LLC (formerly ENvue Medical Holdings, Corp.), a wholly-owned subsidiary of the Company ("ENvue" or "ENvue Medical"). The patent protects the Company's proprietary method of overlaying electromagnetic (EM) navigation data directly onto real-time medical imaging modalities such as X-ray, CT, ultrasound and MRI.

This newly granted patent fortifies ENvue's intellectual property portfolio and protects key technology designed to help clinicians visualize the live path of a feeding tube or catheter directly on medical images. The real-time overlay aims to increase procedural confidence, reduce the risk of misplacement and create efficiencies in hospital workflows.

"Navigation alone is not new," said Doron Besser, M.D., Chief Executive Officer of NanoVibronix. "What sets ENvue apart is our ability to integrate navigation with imaging in real time, a capability now protected by this patent. This differentiation strengthens our leadership in the feeding tube placement market, where precision and workflow efficiency are critical. We believe that it also provides a strong foundation for expansion into vascular navigation, broadening our addressable market and long-term potential. With this addition to our global patent portfolio, we believe that ENvue is well-positioned to lead in both current and future clinical applications."